Who Paid My Doc
Scott Schleifer
Emergency Medicine Mesa, AZ Doctor of Osteopathy
NPI 1578548434 CMS profile 116145
1400 S Dobson Rd, Mesa, AZ 85202
General payments
$1,098
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Scott Schleifer of Mesa, AZ is reported in the CMS Open Payments database as having received $1,098 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 92nd percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $46 | 2 | |
| 2022 | General | $287 | 3 | |
| 2021 | General | $236 | 2 | |
| 2020 | General | $144 | 2 | |
| 2019 | General | $384 | 6 |
Beside peers
- Scott Schleifer
- Emergency Medicine median
- Middle half of Emergency Medicine
- National median
In program year 2025, general payments to Scott Schleifer were reported at $0. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.
Show as a table
| Year | Scott Schleifer | Emergency Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $384 | $51 | $18–$128 | $163 |
| 2020 | $144 | $29 | $16–$99 | $114 |
| 2021 | $236 | $40 | $18–$124 | $132 |
| 2022 | $287 | $49 | $20–$134 | $149 |
| 2023 | $0 | $51 | $22–$142 | $160 |
| 2024 | $46 | $52 | $22–$150 | $164 |
| 2025 | $0 | $57 | $24–$150 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
629
Drug cost
$4,992
Branded share of claims
22.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Paxlovid Nirmatrelvir/Ritonavir | Brand | 15 | $1,314 | |
| Cefdinir | Generic | 42 | $801 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 80 | $635 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 27 | $620 | |
| Doxycycline Hyclate | Generic | 52 | $386 | |
| Ciprofloxacin Hcl | Generic | 28 | $244 | |
| Tramadol Hcl | Generic | 113 | $205 | |
| Prednisone | Generic | 85 | $134 | |
| Metronidazole | Generic | 23 | $126 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 20 | $112 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 154 billing codesPaid by Medicare
$143,178
Medicare patients
421
Services billed
4,548
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 48% | |
| Ischemic heart disease | 33% | |
| Atrial fibrillation | 23% | |
| Chronic kidney disease | 23% | |
| Diabetes | 20% | |
| Osteoporosis | 20% | |
| Cancer | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Infusion, normal saline solution , 1000 cc J7030 | Office | 145 | 184 | $367 |
| Injection, morphine sulfate, up to 10 mg J2270 | Office | 35 | 44 | $149 |
| Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) J2543 | Office | 29 | 111 | $99 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 95 | 178 | $80 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 49 | 510 | $44 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 27 | 108 | $38 |
| Infusion, normal saline solution, 250 cc J7050 | Office | 46 | 60 | $31 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 61 | 272 | $19 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 34 | 43 | $4 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Emergency Medicine in Arizona
Related records
Emergency Medicine in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Emergency Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.